EA
VRTX icon

Everpar Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Everpar Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$490K Buy
986
+67
+7% +$29.7K 0.14% 151
2026
Q1 		$410K Buy
919
+121
+15% +$56.4K 0.14% 154
2025
Q4 		$362K Buy
798
+45
+6% +$19.4K 0.13% 167
2025
Q3 		$295K Sell
753
-39
-5% -$16.3K 0.12% 207
2025
Q2 		$353K Buy
792
+44
+6% +$20.3K 0.16% 172
2025
Q1 		$363K Buy
748
+81
+12% +$37.7K 0.19% 148
2024
Q4 		$269K Sell
667
-26
-4% -$12.1K 0.14% 200
2024
Q3 		$322K Sell
693
-244
-26% -$117K 0.17% 180
2024
Q2 		$439K Buy
937
+387
+70% +$168K 0.22% 143
2024
Q1 		$230K Buy
+550
New +$233K 0.14% 210

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return

Everpar Advisors's VRTX Position: Q2 2026 in Review

Everpar Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 7.3% in Q2 2026, buying an estimated $29.7K and bringing the position to 986 shares worth $490K. The position accounts for 0.14% of the portfolio, ranked #151.

Everpar Advisors first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. 252 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Everpar Advisors held 986 shares of Vertex Pharmaceuticals worth $490K as of Q2 2026.
  • Everpar Advisors bought 67 Vertex Pharmaceuticals shares in Q2 2026, an estimated $29.7K.
  • Vertex Pharmaceuticals made up 0.14% of Everpar Advisors's portfolio in Q2 2026, its #151 holding.
  • Everpar Advisors first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 252 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Everpar Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.